Featured Research

from universities, journals, and other organizations

Agent selectively targets malignant B cells in chronic leukemia, study shows

Date:
May 4, 2011
Source:
Ohio State University Medical Center
Summary:
A new experimental drug called PCI-32765 selectively kills the cancer cells that cause chronic lymphocytic leukemia (CLL), according to a new study. The study shows that the agent selectively kills the malignant B lymphocytes that cause CLL. This is important, the researchers say, because current CLL therapies kill T lymphocytes along with the cancerous B lymphocytes. A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients.

A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James).

The study shows that the experimental agent PCI-32765 selectively kills the malignant B lymphocytes that cause chronic lymphocytic leukemia (CLL).

The researchers say the findings, published online in the journal Blood, are important because current CLL therapies kill T lymphocytes along with the cancerous B lymphocytes.

T lymphocytes and B lymphocytes make up the adaptive immune system. When CLL treatment destroys them both, patients become highly susceptible to life-threatening infections.

"A drug that kills malignant B lymphocytes and spares T lymphocytes could dramatically improve outcomes for CLL patients," says study leader Dr. John C. Byrd, director, division of hematology and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC -- James.

"Our collective results indicate that PCI-32765 is an outstanding candidate for further development as a therapeutic for CLL," says study co-director Dr. Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher with the OSUCCC-James.

The research by Byrd, Johnson and a group of colleagues used CLL cells from ten patients. It had several key findings related to PCI-32765:

  • The agent specifically targets an important signaling molecule called Bruton's tyrosine kinase, which is overexpressed in CLL cells and absent in T cells.
  • The agent inhibits the proliferation of CLL cells in laboratory culture and promotes their death by self-destruction (apoptosis).
  • It blocks survival signals from cells in the surrounding microenvironment, including soluble factors such as IL-6, IL-4, and TNF-a, and stromal-cell contact.

Byrd is the D. Warren Brown Chair of Leukemia Research.

Funding from The Leukemia and Lymphoma Society, the National Cancer Institute and The D. Warren Brown Foundation supported this work.

Other researchers involved in this study were Sarah E. M. Herman, Amber L. Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph Flynn, Jeffrey Jones and Kristie A. Blum of The Ohio State University; and Joseph J. Buggy and Ahmed Hamdy of Pharmacyclics, Inc.

Financial disclosure: Joseph J. Buggy and Ahmed Hamdy are employees of Pharmacyclics, Inc. and both have financial interests in PCI-32765 development.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. E. M. Herman, A. L. Gordon, E. Hertlein, A. Ramanunni, X. Zhang, S. Jaglowski, J. Flynn, J. Jones, K. A. Blum, J. J. Buggy, A. Hamdy, A. J. Johnson, J. C. Byrd. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 2011; DOI: 10.1182/blood-2011-01-328484

Cite This Page:

Ohio State University Medical Center. "Agent selectively targets malignant B cells in chronic leukemia, study shows." ScienceDaily. ScienceDaily, 4 May 2011. <www.sciencedaily.com/releases/2011/05/110503133044.htm>.
Ohio State University Medical Center. (2011, May 4). Agent selectively targets malignant B cells in chronic leukemia, study shows. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2011/05/110503133044.htm
Ohio State University Medical Center. "Agent selectively targets malignant B cells in chronic leukemia, study shows." ScienceDaily. www.sciencedaily.com/releases/2011/05/110503133044.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins